SPOTLIGHT: Xanodyne files IPO
After garnering a total of $232 million in venture funds to buy aaiPharma's pharmaceutical division out of bankruptcy, Xanodyne Pharmaceuticals--which has three products in development in addition to a number of marketed pharmaceuticals--is now planning to go public, filing an $86.2 million IPO. Apax Partners, MPM Capital, AIG, Essex Woodlands Health Ventures, HealthCare Ventures, Aisling Capital and Blue Chip Venture all have a stake in the company. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets